FRLN News and Press, Freeline Therapeutics Holdings plc From 07/23/21

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) traded today at a new 52-week low of $4.89. Approximately 478,000 shares have changed hands today, as compared to an average 30-day volume of 231,000 shares. There is potential upside of 19.5% for shares of Freeline Therapeutics Holdings p...

Shares of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) traded at a new 52-week low today of $5.38. So far today approximately 478,000 shares have been exchanged, as compared to an average 30-day volume of 214,000 shares. Over the past year, Freeline Therapeutics Holdings plc has trad...

Shares of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) traded today at $5.75, breaking its 52-week low. So far today approximately 478,000 shares have been exchanged, as compared to an average 30-day volume of 202,000 shares. Freeline Therapeutics Holdings plc has overhead space with...

Gainers: Freeline Therapeutics (FRLN) +88%, Cytokinetics CYTK +49%, NRx Pharmaceuticals NRXP +37%, Allied Healthcare Products (AHPI) +19%, Aethlon Medical (AEMD) +16%.Losers: China SXT Pharmaceuticals (SXTC) -21%, Atossa Therapeutics (ATOS)&#x...

Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief Scientific Officer role on an interim basis to replace departing Chief Scientific Off...

Lowest dose cohort complete and study positioned for dose escalation Company to present FLT190 data by year-end LONDON, June 16, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical...

Gainers: Organovo (ONVO) +24%, Iterum Therapeutics (ITRM) +16%, Adagene (ADAG) +14%, Freeline Therapeutics (FRLN) +12%, 180 Life Sciences (ATNF) +12%.Losers: Provention Bio (PRVB) -22%, Eton Pharmaceuticals (ETON) -13%, Lannett (LCI) -12%...

Freeline Therapeutics (FRLN): Q1 GAAP EPS of -$0.98 misses by $0.21.Cash and cash equivalents were $195.8 million as of March 31, 2021, as compared to $230.0 million as of December 31, 2020.Based on the company’s current operating plan, Freeline expects that its current level...

FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected to be in the clinic by year-end FLT180a Phase 1/2 dose-...

LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitati...